graph Evidence gap map comparisons
pembrolizumab based treatment
pembrolizumab alone
mBC-Triple negative (TNBC) - 2nd Line (L2) 3
mBC - TNBC - L2 - all population 2   
mBC - TNBC - L2 - PDL1 positive 2    
Comparator:  vs Standard of Care (SoC); 
Risk of bias:  low;   some concerns;   high;  NA;